Defunct Company
Total Trials
12
As Lead Sponsor
11
As Collaborator
1
Total Enrollment
826
NCT01570283
ARMS - Rapidly Generated Multivirus-Specific CTLs for Prophylaxis & Treatment of EBV, CMV, Adenovirus, HHV6 & BK Virus
Phase: Phase 1/2
Role: Lead Sponsor
Start: Sep 30, 2012
Completion: Sep 30, 2017
NCT02108522
Multivirus-specific T Cells for the Treatment of Virus Infections After Stem Cell Transplant
Phase: N/A
Start: Jun 30, 2014
Completion: Dec 31, 2019
NCT02313857
Most Closely Human Leukocyte Antigen (HLA)-Matched CMV-specific T Lymphocytes (Viralym-C)
Phase: Phase 1
Start: Sep 30, 2015
Completion: Feb 28, 2018
NCT02276820
Most Closely Human Leukocyte Antigen (HLA)-Matched Adenovirus-specific T Lymphocytes (Viralym-A)
Start: Dec 7, 2017
NCT02313844
Most Closely Human Leukocyte Antigen (HLA)-Matched BK Virus-specific T Lymphocytes (Viralym-B)
Start: Mar 1, 2018
NCT04401410
Anti-SARS Cov-2 T Cell Infusions for COVID 19
Role: Collaborator
Start: Nov 4, 2020
Completion: Oct 12, 2021
NCT04693637
Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant
Phase: Phase 2/3
Start: Jan 15, 2021
Completion: Jan 19, 2023
NCT04390113
Study to Evaluate Viralym-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis (HC)
Phase: Phase 3
Start: Mar 18, 2021
Completion: Jan 30, 2024
NCT04605484
Study of Posoleucel (Formerly Known as ALVR105; Viralym-M) in Kidney Transplant Patients With BK Viremia
Phase: Phase 2
Start: Mar 22, 2021
Completion: Oct 20, 2022
NCT04933968
Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant
Start: Mar 21, 2022
Completion: Jan 31, 2024
NCT05305040
Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant
Start: Mar 24, 2022
NCT05179057
Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell Transplantation
Start: Apr 26, 2022